Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer

Author(s):
Blok, E.J.; Kroep, J.R.; Kranenbarg, E.M.K.; Duijm-De Carpentier, M.; Putter, H.; Liefers, G.J.; Nortier, J.W.R.; Rutgers, E.J.T.; Seynaeve, C.M.; Velde, C.J.H. van de; IDEAL Study Group; TEAM Study Group
Published
2018
Publication type
Article / Letter to editor
Breast cancerExtended endocrine therapyClinical trialComplianceEarly treatment discontinuationAdverse eventsSurvivalAromatase inhibitorTamoxifen
Date issued
2018-05-31
Language
English
Is part of
European Journal of Cancer (2018), Vol. 95, p. 59-67
hdl
1887/95506
doi
10.1016/j.ejca.2018.03.014